Works by van de Donk, Niels W.C.J.

Results: 29
    1
    2

    Acute and chronic renal artery stenosis.

    Published in:
    European Heart Journal, 2010, v. 31, n. 1, p. 14, doi. 10.1093/eurheartj/ehp455
    By:
    • van de Donk, Niels W.C.J.;
    • Kooij, Nina;
    • Visseren, Frank L.J.
    Publication type:
    Article
    3

    Response to: Interference of daratumumab on the serum protein electrophoresis.

    Published in:
    Clinical Chemistry & Laboratory Medicine, 2017, v. 55, n. 2, p. e29, doi. 10.1515/cclm-2016-1026
    By:
    • McCudden, Christopher;
    • Axel, Amy E.;
    • Slaets, Dominique;
    • Dejoie, Thomas;
    • Clemens, Pamela;
    • Frans, Sandy;
    • Bald, Jaime;
    • Plesner, Torben;
    • Jacobs, Joannes F.M.;
    • van de Donk, Niels W.C.J.;
    • Moreau, Philippe;
    • Schecter, Jordan M.;
    • Ahmadi, Tahamtan;
    • Sasser, A. Kate
    Publication type:
    Article
    4

    PB2132: EXCALIBER‐RRMM: A PHASE 3, TWO‐STAGE STUDY OF IBERDOMIDE, DARATUMUMAB, AND DEXAMETHASONE VERSUS DARATUMUMAB, BORTEZOMIB, AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000975292.31324.26
    By:
    • Lonial, Sagar;
    • Quach, Hang;
    • Dimopoulos, Meletios A.;
    • Rodríguez‐Otero, Paula;
    • Berdeja, Jesus;
    • Richardson, Paul;
    • Kyada, Margee;
    • Chu, Shuyu;
    • Chen, Min;
    • Abad, Patricia;
    • Morando, Juliane;
    • van de Donk, Niels W.C.J.
    Publication type:
    Article
    5

    P1506: TECLISTAMAB REDUCES POLYCLONAL IMMUNOGLOBULIN LEVELS AND IMPAIRS VACCINATION RESPONSES IN HEAVILY PRETREATED MM PATIENTS.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000972904.51933.45
    By:
    • Frerichs, Kristine;
    • Verkleij, Christie;
    • Mateos, Maria‐Victoria;
    • Zweegman, Sonja;
    • Groen, Kaz;
    • Kuipers, Ilse;
    • Martin, Tom;
    • Rodriguez, Cesar;
    • Nooka, Ajay;
    • Kruijswijk, Sandy;
    • Skerget, Sheri;
    • Doyle, Margaret;
    • Banerjee, Arnob;
    • Chastain, Katherine;
    • Perales‐Puchalt, Alfredo;
    • Stephenson, Tara;
    • Uhlar, Clarissa;
    • Kobos, Rachel;
    • Verona, Raluca;
    • van de Donk, Niels W.C.J.
    Publication type:
    Article
    6

    P979: PATIENT‐REPORTED OUTCOMES FOR TECLISTAMAB VERSUS REAL‐WORLD PHYSICIAN’S CHOICE OF THERAPY IN THE LOCOMMOTION STUDY IN PATIENTS WITH TRIPLE‐CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000970820.69075.8f
    By:
    • Moreau, Philippe;
    • van de Donk, Niels W.C.J.;
    • Delforge, Michel;
    • Einsele, Hermann;
    • De Stefano, Valerio;
    • Perrot, Aurore;
    • Besemer, Britta;
    • Pawlyn, Charlotte;
    • Karlin, Lionel;
    • Manier, Salomon;
    • Leleu, Xavier;
    • Thilakarathne, Pushpike;
    • Diels, Joris;
    • Gries, Katharine;
    • Erler‐Yates, Nichola;
    • van Nimwegen, Kirsten;
    • Morano, Raúl;
    • Strulev, Vadim;
    • Haddad, Imene;
    • Kobos, Rachel
    Publication type:
    Article
    7

    P923: COMPARATIVE EFFECTIVENESS OF TALQUETAMAB VS REAL‐WORLD PHYSICIAN’S CHOICE OF TREATMENT IN LOCOMMOTION AND MOMMENT FOR PATIENTS WITH TRIPLE‐CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000970596.51835.28
    By:
    • Einsele, Hermann;
    • Moreau, Philippe;
    • Bahlis, Nizar J;
    • Bhutani, Manisha;
    • Vincent, Laure;
    • Karlin, Lionel;
    • Perrot, Aurore;
    • Goldschmidt, Hartmut;
    • van de Donk, Niels W.C.J.;
    • Ocio, Enrique;
    • Martinez‐Lopez, Joaquín;
    • Rodríguez‐Otero, Paula;
    • Dytfeld, Dominik;
    • Diels, Joris;
    • Strulev, Vadim;
    • Haddad, Imene;
    • Renaud, Thomas;
    • Ammann, Eric;
    • Cabrieto, Jedelyn;
    • Perualila, Nolen
    Publication type:
    Article
    8

    P904: LOCOMMOTION: A PROSPECTIVE, OBSERVATIONAL, MULTINATIONAL STUDY OF REAL‐LIFE CURRENT STANDARDS OF CARE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA– FINAL ANALYSIS AT 2‐YEAR FOLLOW‐UP.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000970520.05307.aa
    By:
    • Moreau, Philippe;
    • Weisel, Katja;
    • De Stefano, Valerio;
    • Goldschmidt, Hartmut;
    • Delforge, Michel;
    • Mohty, Mohamad;
    • Lindsey‐Hill, Joanne;
    • Dytfeld, Dominik;
    • Angelucci, Emanuele;
    • Vincent, Laure;
    • Perrot, Aurore;
    • Benjamin, Reuben;
    • van de Donk, Niels W.C.J.;
    • Ocio, Enrique;
    • In‘t Groen‐Damen, Ester;
    • Roccia, Tito;
    • Schecter, Jordan;
    • Haddad, Imene;
    • Strulev, Vadim;
    • Mitchell, Lada
    Publication type:
    Article
    9

    P892: ANALYSIS OF INFECTIONS AND PARAMETERS OF HUMORAL IMMUNITY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH TALQUETAMAB (TAL) MONOTHERAPY IN MONUMENTAL‐1.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000970472.64690.4e
    By:
    • Rasche, Leo;
    • Schinke, Carolina;
    • Chari, Ajai;
    • Lipe, Brea C.;
    • Lavi, Noa;
    • Rodríguez‐Otero, Paula;
    • Vishwamitra, Deeksha;
    • Skerget, Sheri;
    • Verona, Raluca;
    • MA, Xuewen;
    • Khedkar, Sheetal;
    • Hilder, Brandi;
    • Masterson, Tara;
    • Campagna, Michela;
    • Renaud, Thomas;
    • Tolbert, Jaszianne;
    • Heuck, Christoph;
    • Smit, Damiette;
    • van de Donk, Niels W.C.J.
    Publication type:
    Article
    10

    P877: IXAZOMIB DARATUMUMAB AND LOW‐DOSE DEXAMETHASONE IN INTERMEDIATE‐FIT PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; RESULTS OF THE INDUCTION AND MAINTENANCE TREATMENT OF THE PHASE II HOVON 143 STUDY.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000970412.25266.f8
    By:
    • Groen, Kaz;
    • Stege, Claudia;
    • Nasserinejad, Kazem;
    • de Heer, Koen;
    • van Kampen, Roel J.W.;
    • Leys, Rineke B.L.;
    • Thielen, Noortje;
    • Westerman, Matthijs;
    • Wu, Ka‐Lung;
    • Ludwig, Inge;
    • Issa, Djamila E.;
    • Velders, Gerjo A.;
    • Vekemans, Marie‐Christiane;
    • van de Donk, Niels W.C.J.;
    • Timmers, Gert‐Jan;
    • de Boer, Fransien;
    • Tick, Lidwine W.;
    • van der Spek, Ellen;
    • de Waal, Esther G.M.;
    • Sohne, Maaike
    Publication type:
    Article
    11

    S192: TALQUETAMAB (TAL) + DARATUMUMAB (DARA) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED TRIMM‐2 RESULTS.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000967680.90062.ca
    By:
    • Bahlis, Nizar J;
    • Weisel, Katja;
    • Mateos, Maria‐Victoria;
    • Goldschmidt, Hartmut;
    • Martin, Tom;
    • Morillo, Daniel;
    • Reece, Donna;
    • Rodríguez‐Otero, Paula;
    • Bhutani, Manisha;
    • D’souza, Anita;
    • Oriol, Albert;
    • Rosiñol Dachs, Laura;
    • Dholaria, Bhagirathbhai;
    • Bakshi, Kalpana;
    • Kang, Lijuan;
    • Vandenberk, Lien;
    • Smit, Damiette;
    • Wäsch, Ralph;
    • van de Donk, Niels W.C.J.;
    • Chari, Ajai
    Publication type:
    Article
    12

    S100: FIRST PHASE 3 RESULTS FROM CARTITUDE‐4: CILTA‐CEL VERSUS STANDARD OF CARE (PVD OR DPD) IN LENALIDOMIDE‐REFRACTORY MULTIPLE MYELOMA.

    Published in:
    HemaSphere, 2023, v. 7, p. 1, doi. 10.1097/01.HS9.0000967308.47141.6f
    By:
    • Einsele, Hermann;
    • Yong, Kwee;
    • Harrison, Simon;
    • Mateos, Maria‐Victoria;
    • Moreau, Philippe;
    • van de Donk, Niels W.C.J.;
    • Sidana, Surbhi;
    • Popat, Rakesh;
    • Lendvai, Nikoletta;
    • Lonardi, Carolina;
    • Slaughter, Ana;
    • Schecter, Jordan;
    • LI, Katherine;
    • Zudaire, Enrique;
    • Chen, Diana;
    • Gilbert, Jane;
    • Yeh, Tzu‐Min;
    • Pacaud, Lida;
    • Patel, Nitin;
    • Dhakal, Binod
    Publication type:
    Article
    13

    P879: LONG-TERM FOLLOW-UP FROM MAJESTEC-1 OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN (BCMA) X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM).

    Published in:
    2023
    By:
    • Sidana, Surbhi;
    • Moreau, Philippe;
    • Garfall, Alfred;
    • Bhutani, Manisha;
    • Oriol, Albert;
    • Nooka, Ajay;
    • Martin, Tom;
    • Rosiñol Dachs, Laura;
    • Mateos, Maria-Victoria;
    • Bahlis, Nizar J;
    • Popat, Rakesh;
    • Besemer, Britta;
    • Martinez-Lopez, Joaquín;
    • Krishnan, Amrita;
    • Delforge, Michel;
    • Trancucci, Danielle;
    • Verona, Raluca;
    • Stephenson, Tara;
    • Chastain, Katherine;
    • van de Donk, Niels W.C.J.
    Publication type:
    Abstract
    14
    15

    S191: PIVOTAL PHASE 2 MONUMENTAL-1 RESULTS OF TALQUETAMAB (TAL), A GPRC5DXCD3 BISPECIFIC ANTIBODY (BSAB), FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM).

    Published in:
    2023
    By:
    • Touzeau, Cyrille;
    • Schinke, Carolina;
    • Minnema, Monique;
    • van de Donk, Niels W.C.J.;
    • Rodríguez-Otero, Paula;
    • Mateos, Maria-Victoria;
    • Rasche, Leo;
    • Ye, Jing Christine;
    • Vishwamitra, Deeksha;
    • MA, Xuewen;
    • Qin, Xiang;
    • Campagna, Michela;
    • Masterson, Tara;
    • Hilder, Brandi;
    • Tolbert, Jaszianne;
    • Renaud, Thomas;
    • Goldberg, Jenna;
    • Heuck, Christoph;
    • Chari, Ajai
    Publication type:
    Abstract
    16
    17
    18

    Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 10, p. 665, doi. 10.1016/j.clml.2024.05.003
    By:
    • Chari, Ajai;
    • Krishnan, Amrita;
    • Rasche, Leo;
    • Ye, Jing Christine;
    • Garfall, Alfred;
    • Popat, Rakesh;
    • Lipe, Brea;
    • Qin, Xiang;
    • Campagna, Michela;
    • Masterson, Tara;
    • Tomlinson, Chalmer;
    • Hilder, Brandi;
    • Tolbert, Jaszianne;
    • Renaud, Thomas;
    • Smit, M. Damiette;
    • Gray, Kathleen;
    • Kane, Colleen;
    • Heuck, Christoph;
    • Donk, Niels W.C.J. van de
    Publication type:
    Article
    19
    20
    21

    P-203: EXCALIBER: a phase 3 study comparing iberdomide, daratumumab, and dexamethasone (IberDd) with daratumumab, bortezomib, and dexamethasone (DVd) in patients with relapsed or refractory multiple myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S150, doi. 10.1016/S2152-2650(21)02330-2
    By:
    • Lonial, Sagar;
    • Berdeja, Jesus G.;
    • Dimopoulos, Meletios-Athanasios;
    • Jagannath, Sundar;
    • Knop, Stefan;
    • Hang Quach;
    • Rodríguez-Otero, Paula;
    • Richardson, Paul G.;
    • Sorrell, April;
    • Min Chen;
    • Kueenburg, Elisabeth;
    • Tuong Vi Nguyen;
    • Hong, Kevin;
    • Peluso, Teresa;
    • van de Donk, Niels W.C.J.
    Publication type:
    Article
    22

    P-155: Incidence, mitigation, and management of neurologic adverse events in CARTITUDE-2, a phase 2 study of ciltacabtagene autoleucel (cilta-cel) in patients with Multiple Myeloma.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S120, doi. 10.1016/S2152-2650(21)02282-5
    By:
    • Einsele, Hermann;
    • Parekh, Samir;
    • Madduri, Deepu;
    • Santomasso, Bianca;
    • Pérez-Larraya, Jaime Gállego;
    • van de Donk, Niels W.C.J.;
    • Arnulf, Bertrand;
    • Mateos, María-Victoria;
    • De Braganca, Kevin C.;
    • Varsos, Helen;
    • Carrasco-Alfonso, Marlene J.;
    • Akram, Muhammad;
    • Lendvai, Nikoletta;
    • Jackson, Carolyn C.;
    • Olyslager, Yunsi;
    • Zudaire, Enrique;
    • Li, Claire;
    • Dong Geng;
    • Jakubowiak, Andrzej;
    • Cohen, Adam
    Publication type:
    Article
    23

    OAB-025: Talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D)×CD3 bispecific antibody, in relapsed/refractory multiple myeloma (RRMM): Updated results of a phase 1, first-in-human study.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S16, doi. 10.1016/S2152-2650(21)02099-1
    By:
    • Donk, Niels W.C.J. van de;
    • Krishnan, Amrita;
    • Oriol, A;
    • Berdeja, Jesus G.;
    • Rodríguez-Otero, Paula;
    • Askari, Elham;
    • Mateos, María-Victoria;
    • Minnema, Monique C.;
    • Costa, Luciano;
    • Verona, Raluca;
    • Girgis, Suzette;
    • Prior, Thomas;
    • Hilder, Brandi;
    • Russell, Jeffery;
    • Goldberg, Jenna;
    • Chari, Ajai
    Publication type:
    Article
    24

    OAB-013: Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S9, doi. 10.1016/S2152-2650(21)02087-5
    By:
    • Lonial, Sagar;
    • Richardson, Paul G.;
    • Popat, Rakesh;
    • Stadtmauer, Edward A.;
    • Larsen, Jeremy T.;
    • Oriol, A.;
    • Knop, Stefan;
    • Jagannath, Sundar;
    • Cook, Gordon;
    • Badros, Ashraf Z.;
    • Rodríguez-Otero, Paula;
    • Siegel, David S.;
    • Tuong Vi Nguyen;
    • Micco, Antonia Di;
    • Amin, Alpesh;
    • Min Chen;
    • Kueenburg, Elisabeth;
    • van de Donk, Niels W.C.J.
    Publication type:
    Article
    25

    OAB-008: Identification of high-risk Multiple Myeloma with a plasma cell Leukemia-like transcriptomic profile.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S6, doi. 10.1016/S2152-2650(21)02082-6
    By:
    • Bruinink, Davine Hofste op;
    • Kuiper, Rowan;
    • Duin, Mark van;
    • Cupedo, Tom;
    • Velden, Vincent H.J. van der;
    • Hoogenboezem, Remco;
    • Holt, Bronno van der;
    • Beverloo, H. Berna;
    • Valent, Erik T.;
    • Vermeulen, Michael;
    • Gay, Francesca;
    • Broijl, Annemiek;
    • Avet-Loiseau, Hervé;
    • Munshi, Nikhil C.;
    • Musto, Pellegrino;
    • Moreau, Philippe;
    • Zweegman, Sonja;
    • Donk, Niels W.C.J. van de;
    • Sonneveld, Pieter
    Publication type:
    Article
    26

    MM-112: Incidence, Mitigation, and Management of Neurologic Adverse Events in the CARTITUDE-2 Study of Patients with Multiple Myeloma Treated with Ciltacabtagene Autoleucel (Cilta-Cel).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S421, doi. 10.1016/S2152-2650(21)01945-5
    By:
    • Jakubowiak, Andrzej;
    • Parekh, Samir;
    • Madduri, Deepu;
    • Santomasso, Bianca;
    • Pérez-Larraya, Jaime Gállego;
    • van de Donk, Niels W.C.J.;
    • Arnulf, Bertrand;
    • Mateos, Maria-Victoria;
    • De Braganca, Kevin C.;
    • Varsos, Helen;
    • Carrasco-Alfonso, Marlene J.;
    • Akram, Muhammad;
    • Lendvai, Nikoletta;
    • Jackson, Carolyn C.;
    • Olyslager, Yunsi;
    • Zudaire, Enrique;
    • Li, Claire;
    • Geng, Dong;
    • Einsele, Hermann;
    • Cohen, Adam
    Publication type:
    Article
    27

    Poster: MM-112: Incidence, Mitigation, and Management of Neurologic Adverse Events in the CARTITUDE-2 Study of Patients with Multiple Myeloma Treated with Ciltacabtagene Autoleucel (Cilta-Cel).

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S249, doi. 10.1016/S2152-2650(21)01568-8
    By:
    • Jakubowiak, Andrzej;
    • Parekh, Samir;
    • Madduri, Deepu;
    • Santomasso, Bianca;
    • Pérez-Larraya, Jaime Gállego;
    • van de Donk, Niels W.C.J.;
    • Arnulf, Bertrand;
    • Mateos, Maria-Victoria;
    • De Braganca, Kevin C.;
    • Varsos, Helen;
    • Carrasco-Alfonso, Marlene J.;
    • Akram, Muhammad;
    • Lendvai, Nikoletta;
    • Jackson, Carolyn C.;
    • Olyslager, Yunsi;
    • Zudaire, Enrique;
    • Li, Claire;
    • Geng, Dong;
    • Einsele, Hermann;
    • Cohen, Adam
    Publication type:
    Article
    28
    29